The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis — possible applications of anti-RANKL antibody to the treatment of cancer patients

DOI Web Site Web Site PubMed 36 References
  • Yasuda Hisataka
    Nagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd.

Bibliographic Information

Other Title
  • 抗RANKL抗体製剤の作用機序―骨粗鬆症治療薬からがん治療薬への適用拡大の可能性―
  • コウRANKL コウタイ セイザイ ノ サヨウ キジョ : コツソショウショウ チリョウヤク カラ ガン チリョウヤク エ ノ テキヨウ カクダイ ノ カノウセイ

Search this article

Abstract

<p>Discovery of RANKL (receptor activator of NF-κB ligand) gave a great impact on identification of the mechanisms regulating osteoclast differentiation and function, establishment of research field bridging bone and mineral research and immunology (osteoimmunology), and development of a fully human anti-RANKL monoclonal neutralizing antibody (denosumab). Denosumab has been clinically available for treatment of osteoporosis and cancer-induced bone diseases in the US, Europe and many countries including Japan. Denosumab is a so-called blockbuster of which sales amount was 3.9 billion US dollars in 2017. Because RANKL is the absolute factor for osteoclast differentiation, anti-RANKL antibody is very effective and its application is good news for many patients. Recent topics are the identification of importance of RANKL on osteoblasts in regulation of osteogenesis and the demonstration of RANKL-RANK (the receptor of RANKL) dual signaling in coupling between bone resorption and bone formation. RANKL reverse signaling that we had hypothesized was demonstrated at last. In this review I describe the mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis. I also suggest possible applications of anti-RANKL antibody to the treatment of cancer patients.</p>

Journal

References(36)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top